Get intelligentvalue.com

Own it today or select a payment plan

Buy Now$3,879Payment Plan$325/mo

Secured by Stripe

Premium Domain Name

intelligentvalue.com

is available for purchase

243 views

Visitors from

US 53%·

AU 33%·

IN 7%·

GB 2%·

FR 1%

Perfect for

Financial Consulting Technology Startups Educational Services Economic Forecasting E-commerce Solutions Business Analytics Artificial Intelligence Solutions Investment Advisory Strategic Planning Market Research

Unlock the potential of 'intelligentvalue.com', a premium domain that embodies sophistication and expertise in investment advisory and financial consulting. Perfect for businesses in artificial intelligence solutions, market research, and strategic planning, this memorable domain conveys a strong branding message that resonates with clients seeking innovative and data-driven insights. Elevate your presence in the competitive landscape with a digital identity that signifies intelligence, value, and forward-thinking solutions.

Safe & Secure

Protected transactions with Stripe

Fast Transfer

Domain transferred within 24 hours

Flexible Payments

Interest-free payment plans available

Stryker's Q1 2026 Earnings: What to Expect

April 20, 2026 at 13:06 PM EDT

ⓘ This article is third-party content and does not represent the views of this site. We make no guarantees regarding its accuracy or completeness.

Valued at a market cap of $131.5 billion, Stryker Corporation (SYK) is a medical technology company that is widely recognized for its market-leading Mako robotic-arm assisted surgery platform and a diverse portfolio that includes joint replacement implants, surgical equipment, and neurovascular intervention tools. The Portage, Michigan-based company is expected to announce its fiscal Q1 earnings for 2026 after the market closes on Thursday, Apr. 30.

Ahead of this event, analysts expect this healthcare company to report a profit of $2.99 per share, up 5.3% from $2.84 per share in the year-ago quarter. The company has topped Wall Street’s bottom-line estimates in each of the last four quarters. In Q4 2025, SYK’s EPS of $4.47 outpaced the consensus expectations by 1.6%.

More Top Stocks Daily: Go behind Wall Street’s hottest headlines with Barchart’s Active Investor newsletter.

For the current fiscal year, ending in December, analysts expect SYK to report earnings of $14.92 per share, up 9.5% from $13.63 per share in fiscal 2025. Its EPS is expected to further grow 11.1% year-over-year to $16.57 in fiscal 2027.

SYK has declined 1.7% over the past 52 weeks, considerably underperforming both the S&P 500 Index's ($SPX) 34.9% return and the State Street Health Care Select Sector SPDR ETF’s (XLV) 9.8% uptick over the same time period.

On Mar. 16, shares of SYK rose 3.8% as investors bought the dip following a sharp recent decline triggered by a cyberattack. The stock had previously suffered a significant correction after the company revealed that a breach linked to the pro-Iranian group Handala had wiped data from more than 200,000 systems, disrupting order processing, manufacturing, and shipping.

Despite these disruptions, Stryker confirmed that its products remained safe. The rebound suggests investors viewed the sell-off as excessive, a view supported by analysts at Jefferies Financial Group Inc. (JEF) and William Blair, who maintained “Outperform” ratings, citing the company’s strong underlying business.

Wall Street analysts are moderately optimistic about SYK’s stock, with a "Moderate Buy" rating overall. Among 28 analysts covering the stock, 18 recommend "Strong Buy," three indicate "Moderate Buy,” and seven suggest "Hold." The mean price target for SYK is $422.30, indicating a 24.4% potential upside from the current levels.

On the date of publication, Neharika Jain did not have (either directly or indirectly) positions in any of the securities mentioned in this article. All information and data in this article is solely for informational purposes. For more information please view the Barchart Disclosure Policy here.

More news from Barchart

Report this content

If you believe this article contains misleading, harmful, or spam content, please let us know.

Report this article